Inhibiting myeloperoxidase prevents onset and reverses established high-fat diet-induced microvascular insulin

Weidong Chai1, Kevin Aylor1, Zhenqi Liu1

  • 1Division of Endocrinology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.

Insights

Inhibiting myeloperoxidase (MPO) selectively improves vascular insulin resistance caused by high-fat diets. This suggests MPO inhibitors may prevent vascular dysfunction in insulin-resistant individuals.

Area of Science:

  • Biomedical Science
  • Metabolic Disease Research
  • Cardiovascular Physiology

Background:

  • High-fat diets (HFD) rapidly induce insulin resistance (IR), affecting neutrophils and microvasculature.
  • Myeloperoxidase (MPO), abundant in neutrophils, inhibits vasodilation and is linked to cardiovascular disease.
  • Previous studies show MPO inhibition blunts metabolic IR in mice, but its effect on microvascular IR is unclear.

Purpose of the Study:

  • To investigate if MPO inhibition prevents or reverses HFD-induced metabolic and microvascular IR in rats.
  • To determine the specific effects of MPO inhibition on insulin sensitivity in muscle tissue.

Main Methods:

  • Utilized contrast-enhanced ultrasound and euglycemic insulin clamp techniques in Sprague-Dawley rats.
  • Administered continuous subcutaneous AZD5904 (an MPO inhibitor) during HFD feeding.
  • Assessed insulin-mediated skeletal muscle capillary recruitment, glucose utilization, and insulin signaling.

Main Results:

  • Two weeks of HFD impaired insulin-mediated capillary recruitment and glucose utilization in muscle.
  • AZD5904 infusion during HFD selectively blocked the microvascular effects of the diet.
  • AZD5904 administration in the later HFD period restored microvascular insulin sensitivity but not overall metabolic IR.

Conclusions:

  • MPO inhibition demonstrates a selective therapeutic effect on vascular insulin resistance.
  • Targeting MPO may offer a strategy to prevent vascular complications associated with insulin resistance.
  • Further research could explore MPO inhibitors for managing vascular dysfunction in IR patients.